Form 8-K · Current Report · Filed 2026-04-27
Johnson & Johnson Shareholders Approve Key Proposals at 2026 Annual Meeting
At the 2026 Annual Meeting of Shareholders, Johnson & Johnson's shareholders elected all 12 director nominees to the Board of Directors, approved the executive compensation philosophy and compensation of named executive officers on an advisory basis, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and did not approve the shareholder proposal to adopt a policy requiring an independent board chair.
- Filer
- Johnson & Johnson JNJ · NYSE
- Filed
- Accession
- 0000200406-26-000089
- CIK
- 0000200406
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$227.50
Next session
+0.1%
Since filing
+12.7%
Latest close
$256.35
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from JNJ reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, JNJ insiders reported 6 Form 4 transactions — net selling of $1.1M.
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Never miss another JNJ filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.